Pharmacoeconomic aspects of the treatment of diabetic foot syndrome

Abstract

Treatment of patients with diabetic foot syndrome (DFS) is a major medico-social problem facing public health services. One of its important aspectsis high cost of the treatment. In connection with this, not only medical but also economic issues pertinent to DFS have recently been widely discussedin different countries. Clinico-economic analysis of the use of new medicinal products, therapeutic modalities, and established medical technologiesis of primary importance for making decisions concerning allocation of available financial resources. The present review of foreign publications focuseson the studies providing additional arguments in favour of modern efficacious methods for the management of DFS. The review is intended to motivateclinicians and health officials to revise current approaches to the treatment of DFS patients in this country.

"The State of Renal Function in Patients with Severe Complications of Diabetic Foot Syndrome (Ulcer, Gangrene, Amputation) Associated with Chronic Kidney Disease"

“…One of the complications that determine the high risk of disability and mortality in patients with type 2 diabetes with ESRD on dialysis is DFS. According to the authors [8][9][10][11], in patients with DM with the onset of ESRD (uremia), the risk of DFS increases by more than five times. With the initiation of renal replacement therapy, the frequency of DFS increases significantly [12][13][14].…”

Assessment of changes in the lesions sizes and the incidence of complete epithelialization during the treatment of diabetic foot syndrome over a period of 4 weeks (multicenter study)

“…Длительно незаживающие язвы и гнойнонекротические процессы у пациентов с СДС являются причиной ампутаций, доля которых достигает 70% среди всех причин нетравматической ампутации конечностей [3]. Это приводит к росту инвалидизации [4,6,7,9,13,14] и значительному повыше-doi: 10.17116/hirurgia2017355-60…”